Purinethol
(Mercaptopurine)ApprovedSmall molecule
Mercaptopurine is used to treat certain types of cancer, particularly acute leukemia, and autoimmune diseases like inflammatory bowel disease by suppressing the immune system and stopping cancer cells from growing.[2] Purinethol is currently approved and in use across 13 indications[4].[1]
Purinethol is one of 179 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Approved.
13
Indications
146
Total Trials
38
Active Trials
178
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
148 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Purinethol
SStason
Approved
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cellcept
RochePhase 3
Iclusig
TakedaPhase 3
Arranon
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia79 trials
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Show 76 more trials
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT05157971·24 enrolled
Acute Promyelocytic Leukemia8 trials
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Leukemia6 trials
B Acute Lymphoblastic Leukemia5 trials
Show 2 more trials
Lymphoma4 trials
34 more indications
Lymphoblastic Lymphoma4 trials
Acute Leukemia of Ambiguous Lineage3 trials
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled
Treatment2 trials
Langerhans Cell Histiocytosis2 trials
Adult Acute Lymphoblastic Leukemia2 trials
T Acute Lymphoblastic Leukemia2 trials
Myelodysplastic Syndrome1 trial
Inflammatory Disease1 trial
Brain Neoplasm1 trial
Precursor B-Cell Acute Lymphoblastic Leukemia1 trial
Randomized Controlled Trial1 trial
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Completed·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT02177071·211 enrolled
Bone Marrow Transplantation1 trial
B-cell acute lymphoblastic leukemia1 trial
Hematologic Malignancies1 trial
Fasting Conditions1 trial
Ulcerative Colitis1 trial
Mercaptopurine Therapy in Ulcerative Colitis
Unknown status·—·Phase 3·NCT02910245·136 enrolled
Acute Lymphoid Leukemia1 trial
Recurrent B Acute Lymphoblastic Leukemia1 trial
Refractory Acute Lymphoblastic Leukemia1 trial
Down syndrome1 trial
Kidney Cancer1 trial
T lymphoblastic leukemia/lymphoma1 trial
Acute Lymphoblastic Leukemia, Pediatric1 trial
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
PURINETHOL
NDA NDA009053
Apr 28, 2014
PURIXAN
NDA NDA205919
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Purinethol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Mercaptopurine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]